





Genomic Health INC
Rank 16 of 66

The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 111% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 73% points above the market average of 150%.

Input Variable	Value in 1000 USD
Assets, Current	145,964
Assets, Non-Current	9,462
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	73,272
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	41,175
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-1,554
Other Expenses	58,644
Other Liabilities	0
Other Net Income	2,894
Other Revenues	327,868
Property Plant and Equipment	45,688
Research And Development Expense	61,723
Selling and Marketing Expense	151,042

Output Variable	Value in 1000 USD
Assets	201,114
Liabilities	41,175
Expenses	344,681
Revenues	327,868
Stockholders Equity	159,939
Net Income	-13,919
Comprehensive Net Income	-15,473
BaseVar	459,643
ECR before LimitedLiability	179%
Economic Capital Ratio	224%